Literature DB >> 27846763

Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma.

Adam Holtzman1, Christopher G Morris1, Robert J Amdur1, Peter T Dziegielewski2, Brian Boyce2, William M Mendenhall1.   

Abstract

BACKGROUND: We report long-term outcomes of patients treated with primary radiotherapy (RT) or surgery and adjuvant RT for salivary gland malignancies.
MATERIALS AND METHODS: From 1964 to 2012, 291 patients received primary RT (n = 67) or RT combined with surgery (n = 224).
RESULTS: The 5-, 10-, and 15-year local control, local-regional control, distant metastasis-free survival, cause-specific survival and overall survival rates were 82%, 77% and 73%; 77%, 72% and 67%; 74%, 70% and 70%; 70%, 59% and 54%; and 63%, 47% and 38%, respectively. Per multivariate analysis, combined surgery and RT and T stage impacted local control; overall stage and combined surgery and RT impacted local-regional control; overall stage impacted distant metastasis-free survival; and overall stage, node positivity, clinical nerve invasion, and surgery and RT impacted cause-specific and overall survival. Five percent of patients experienced grade 3 or worse toxicity.
CONCLUSION: Combined surgery and RT improves local control, local-regional control, and cause-specific survival compared with primary RT for salivary tumors.

Entities:  

Mesh:

Year:  2016        PMID: 27846763     DOI: 10.1080/0284186X.2016.1253863

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  Development and validation of nomograms for predicting survival and recurrence in patients with parotid gland cancer.

Authors:  Zhigong Wei; Zhuang Zhang; Lianlian Yang; Ling He; Zheran Liu; Yan He; Jingjing Wang; Xiaoli Mu; Ruidan Li; Yan Huang; Xingchen Peng
Journal:  Gland Surg       Date:  2021-08

2.  Prediction of Recurrence by Machine Learning in Salivary Gland Cancer Patients After Adjuvant (Chemo)Radiotherapy.

Authors:  Francesca De Felice; Valentino Valentini; Marco De Vincentiis; Cira Rosaria Tiziana Di Gioia; Daniela Musio; Aida Angela Tummolo; Ludovica Isabella Ricci; Valeria Converti; Silvia Mezi; Daniela Messineo; Gianluca Tenore; Marco Della Monaca; Massimo Ralli; Francesco Vullo; Andrea Botticelli; Edoardo Brauner; Paolo Priore; Romeo Umberto; Paolo Marchetti; Carlo Della Rocca; Antonella Polimeni; Vincenzo Tombolini
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.406

3.  Carbon-ion radiotherapy in accelerated hypofractionated active raster-scanning technique for malignant lacrimal gland tumors: feasibility and safety.

Authors:  Sati Akbaba; Kristin Lang; Thomas Held; Klaus Herfarth; Juliane Rieber; Peter Plinkert; Gerd U Auffarth; Stefan Rieken; Juergen Debus; Sebastian Adeberg
Journal:  Cancer Manag Res       Date:  2019-02-01       Impact factor: 3.989

4.  Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study.

Authors:  Benjamin Gravesteijn; Eline Krijkamp; Jan Busschbach; Geert Geleijnse; Isabel Retel Helmrich; Sophie Bruinsma; Céline van Lint; Ernest van Veen; Ewout Steyerberg; Kees Verhoef; Jan van Saase; Hester Lingsma; Rob Baatenburg de Jong
Journal:  Value Health       Date:  2021-03-05       Impact factor: 5.725

Review 5.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.